Open AccessCanagliflozin and cardiovascular outcomes in Type 2 diabetes
Author(s) -
Ashish Sarraju,
Gabriela SpencerBonilla,
Fátima Rodríguez,
Kenneth W. Mahaffey
Publication year - 2021
Publication title -
future cardiology
Language(s) - English
Resource type - Journals
eISSN - 1744-8298
pISSN - 1479-6678
DOI - 10.2217/fca-2020-0029
Subject(s) - canagliflozin , medicine , diabetes mellitus , type 2 diabetes mellitus , clinical trial , placebo , type 2 diabetes , randomized controlled trial , adverse effect , intensive care medicine , endocrinology , alternative medicine , pathology
SGLT2 inhibitors have risen to prominence in recent years as Type 2 diabetes mellitus medications with favorable effects on cardiovascular (CV) and renal outcomes. Canagliflozin is a US FDA-approved SGLT2 inhibitor that has demonstrated CV and renal outcome benefits in large scale placebo-controlled randomized trials of patients with Type 2 diabetes mellitus and elevated CV risk. Canagliflozin use may also be associated with serious and nonserious adverse effects requiring ongoing monitoring in patients initiated on this medication. This paper provides a detailed overview of canagliflozin including its pharmacologic profile, clinical efficacy and safety data, with discussion of both clinical trial results, as well as real-world evidence.